Half-year report · HY
3055.TEDINET S100WZRI
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥148.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥289.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥141.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥910m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.6bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.8bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥884m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥884m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥157.5bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥147.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥149.6bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥94.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥85.6bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥63.3bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥61.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥60.8bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.4bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥17.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.4bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.8bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥262m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥856m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥249m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥990m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥696m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥54.44 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥116.44 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.26 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.2% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.6% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Otherother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥17m |
| Otherother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Otherother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥567m |
| Dispensing Industryreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥6.3bn |
| Dispensing Industryreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥6.3bn |
| Dispensing Industryreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4m |
| Dispensing Industryreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥8m |
| Information And Communication Technology Industryreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.0bn |
| Information And Communication Technology Industryreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥307m |
| Information And Communication Technology Industryreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥739m |
| Information And Communication Technology Industryreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥59m |
| Medical Equipment Wholesale Industryreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥33.7bn |
| Medical Equipment Wholesale Industryreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥33.5bn |
| Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥221m |
| Medical Equipment Wholesale Industryreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥354m |
| Nursing Industryreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥2.2bn |
| Nursing Industryreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.2bn |
| Nursing Industryreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1m |
| Nursing Industryreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥180m |
| Wholesaler Of Drugs Industryreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥110.2bn |
| Wholesaler Of Drugs Industryreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥106.2bn |
| Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| Wholesaler Of Drugs Industryreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥636m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥154.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥148.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥1.8bn |
| Otherother segments | revenue | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| Otherother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥33m |
| Otherother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Otherother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥566m |
| Dispensing Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Dispensing Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Dispensing Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5m |
| Dispensing Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥5m |
| Information And Communication Technology Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.0bn |
| Information And Communication Technology Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥289m |
| Information And Communication Technology Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥712m |
| Information And Communication Technology Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥22m |
| Medical Equipment Wholesale Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥34.1bn |
| Medical Equipment Wholesale Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥33.8bn |
| Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥309m |
| Medical Equipment Wholesale Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥407m |
| Nursing Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| Nursing Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| Nursing Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2m |
| Nursing Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥142m |
| Wholesaler Of Drugs Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥102.8bn |
| Wholesaler Of Drugs Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥98.6bn |
| Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| Wholesaler Of Drugs Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥750m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥147.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥141.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 561
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of property plant and equipment inv cf | Prior1InterimDuration | -1264000000 | JPY |
| Purchase of property plant and equipment inv cf | InterimDuration | -1299000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1InterimDuration | 25000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | InterimDuration | 0 | JPY |
| Purchase of intangible assets inv cf | Prior1InterimDuration | -171000000 | JPY |
| Purchase of intangible assets inv cf | InterimDuration | -260000000 | JPY |
| Proceeds from sales of intangible assets inv cf | Prior1InterimDuration | － | JPY |
| Proceeds from sales of intangible assets inv cf | InterimDuration | 0 | JPY |
| Purchase of investment securities inv cf | Prior1InterimDuration | -11000000 | JPY |
| Purchase of investment securities inv cf | InterimDuration | -11000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1InterimDuration | － | JPY |
| Proceeds from sales of investment securities inv cf | InterimDuration | 720000000 | JPY |
| Payments of loans receivable inv cf | Prior1InterimDuration | － | JPY |
| Payments of loans receivable inv cf | InterimDuration | -3000000 | JPY |
| Collection of loans receivable inv cf | Prior1InterimDuration | 23000000 | JPY |
| Collection of loans receivable inv cf | InterimDuration | 6000000 | JPY |
| Proceeds from cancellation of insurance funds inv cf | Prior1InterimDuration | 163000000 | JPY |
| Proceeds from cancellation of insurance funds inv cf | InterimDuration | － | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1InterimDuration | -70000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | InterimDuration | － | JPY |
| Payments for retirement of noncurrent assets inv cf | Prior1InterimDuration | -1000000 | JPY |
| Payments for retirement of noncurrent assets inv cf | InterimDuration | -8000000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | -1305000000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | -856000000 | JPY |
| Decrease in short term loans payable fin cf | Prior1InterimDuration | -15000000 | JPY |
| Decrease in short term loans payable fin cf | InterimDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -32000000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -0 | JPY |
| Decrease increase in treasury stock fin cf | Prior1InterimDuration | -389000000 | JPY |
| Decrease increase in treasury stock fin cf | InterimDuration | -0 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -215000000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -209000000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration | -42000000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration | -39000000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -696000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -249000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | － | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | － | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | 296000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | 3644000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 20813000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 17739000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 21109000000 | JPY |
| Cash and cash equivalents | InterimInstant | 21383000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 98643000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 33767000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E03003-000DispensingIndustryReportableSegmentsMember | 6343000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E03003-000NursingIndustryReportableSegmentsMember | 2128000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 289000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OtherReportableSegmentsMember | 33000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |